G Michael1, J Dempster, K A Kane, S J Coker. 1. Strathclyde Institute of Pharmacy and Biomedical Sciences, Division of Physiology and Pharmacology, University of Strathclyde, Glasgow, UK.
Abstract
BACKGROUND AND PURPOSE: Torsade de pointes (TdP) can be induced by a reduction in cardiac repolarizing capacity. The aim of this study was to assess whether IKs blockade or enhancement of INa could potentiate TdP induced by IKr blockade and to investigate whether short-term variability (STV) or triangulation of action potentials preceded TdP. EXPERIMENTAL APPROACH: Experiments were performed in open-chest, pentobarbital-anaesthetized, alpha 1-adrenoceptor-stimulated, male New Zealand White rabbits, which received three consecutive i.v. infusions of either the IKr blocker E-4031 (1, 3 and 10 nmol kg(-1) min(-1)), the IKs blocker HMR1556 (25, 75 and 250 nmol kg(-1) min(-1)) or E-4031 and HMR1556 combined. In a second study rabbits received either the same doses of E-4031, the INa enhancer, ATX-II (0.4, 1.2 and 4.0 nmol kg(-1)) or both of these drugs. ECGs and epicardial monophasic action potentials were recorded. KEY RESULTS: HMR1556 alone did not cause TdP but increased E-4031-induced TdP from 25 to 80%. ATX-II alone caused TdP in 38% of rabbits, as did E-4031; 75% of rabbits receiving both drugs had TdP. QT intervals were prolonged by all drugs but the extent of QT prolongation was not related to the occurrence of TdP. No changes in STV were detected and triangulation was only increased after TdP occurred. CONCLUSIONS AND IMPLICATIONS: Giving modulators of ion channels in combination substantially increased TdP but, in this model, neither STV nor triangulation of action potentials could predict TdP.
BACKGROUND AND PURPOSE:Torsade de pointes (TdP) can be induced by a reduction in cardiac repolarizing capacity. The aim of this study was to assess whether IKs blockade or enhancement of INa could potentiate TdP induced by IKr blockade and to investigate whether short-term variability (STV) or triangulation of action potentials preceded TdP. EXPERIMENTAL APPROACH: Experiments were performed in open-chest, pentobarbital-anaesthetized, alpha 1-adrenoceptor-stimulated, male New Zealand White rabbits, which received three consecutive i.v. infusions of either the IKr blocker E-4031 (1, 3 and 10 nmol kg(-1) min(-1)), the IKs blocker HMR1556 (25, 75 and 250 nmol kg(-1) min(-1)) or E-4031 and HMR1556 combined. In a second study rabbits received either the same doses of E-4031, the INa enhancer, ATX-II (0.4, 1.2 and 4.0 nmol kg(-1)) or both of these drugs. ECGs and epicardial monophasic action potentials were recorded. KEY RESULTS: HMR1556 alone did not cause TdP but increased E-4031-induced TdP from 25 to 80%. ATX-II alone caused TdP in 38% of rabbits, as did E-4031; 75% of rabbits receiving both drugs had TdP. QT intervals were prolonged by all drugs but the extent of QT prolongation was not related to the occurrence of TdP. No changes in STV were detected and triangulation was only increased after TdP occurred. CONCLUSIONS AND IMPLICATIONS: Giving modulators of ion channels in combination substantially increased TdP but, in this model, neither STV nor triangulation of action potentials could predict TdP.
Authors: Morten B Thomsen; S Cora Verduyn; Milan Stengl; Jet D M Beekman; Geert de Pater; Jurren van Opstal; Paul G A Volders; Marc A Vos Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: Paul G A Volders; Milan Stengl; Jurren M van Opstal; Uwe Gerlach; Roel L H M G Spätjens; Jet D M Beekman; Karin R Sipido; Marc A Vos Journal: Circulation Date: 2003-05-19 Impact factor: 29.690
Authors: M J Walker; M J Curtis; D J Hearse; R W Campbell; M J Janse; D M Yellon; S M Cobbe; S J Coker; J B Harness; D W Harron Journal: Cardiovasc Res Date: 1988-07 Impact factor: 10.787
Authors: Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Balázs Horváth; Ferenc Ruzsnavszky; Krisztina Váczi; János Magyar; Tamás Bányász; András Varró; Péter P Nánási Journal: Pflugers Arch Date: 2014-08-02 Impact factor: 3.657
Authors: Attila S Farkas; László Rudas; Péter Makra; Norbert Csík; István Leprán; Tamás Forster; Miklós Csanády; Julius Gy Papp; András Varró; András Farkas Journal: Br J Pharmacol Date: 2010-12 Impact factor: 8.739
Authors: Attila S Farkas; Péter Makra; Norbert Csík; Szabolcs Orosz; Michael J Shattock; Ferenc Fülöp; Tamás Forster; Miklós Csanády; Julius Gy Papp; András Varró; András Farkas Journal: Br J Pharmacol Date: 2009-02-16 Impact factor: 8.739
Authors: W Victor R Vieweg; Jules C Hancox; Mehrul Hasnain; Jayanthi N Koneru; Michael Gysel; Adrian Baranchuk Journal: Ther Adv Infect Dis Date: 2013-08